

INCREASING MAT CAPACITY FOR CHRONIC OPIOID USE AND OUD

Victor Wu, MD MPH Chief Medical Officer, TennCare August 14th, 2018


Wu, TennCare


The impact of the Opioid Epidemic within


TennCare


TennCare has been actively engaged in fighting the opioid epidemic


- · Pharmacy lock-in program
- Opioid Preferred Drug List (PDL)
- Increased prior authorization and clinical criteria for controlled substances
- Implementation of State of TN/CDC chronic pain guidelines
- 7-day first fill requirement
- Top 100 Prescribers report card
- Statewide collaborative efforts including NAS subcabinet, Governor's Children's Cabinet, and buprenorphine treatment guidelines committee











TennCare's Opioid Strategy

Primary Prevention

limit opioid exposure to prevent progression to chronic opioid use

Non-Chronic and First Time Users of Opioids

- Implemented rule on Jan 16 placing dosage and day coverage allowances on opioid prescriptions for naïve and acute users.
- Improve access to non-opioid pain medication therapies
- Increased prior authorization requirements for all opioid refills
- Served on Governor's Opioid Taskforce that led to passage of TN Together legislation focusing on statewide response to opioid epidemic
- MCOs will continue to cover and educate providers and members about non-pharmacological pain management and provide clinical services such as physical therapy

Secondary Prevention

early detection and intervention to reduce impact of opioid misuse

Women of Child Bearing Age & Provider Education

- Launched state-wide initiative to increase inpatient post-partum LARC access for women immediately after delivery
- Developed claims-based algorithm for women of child bearing age using opioids to determine clinical risk related to opioid use (e.g. OUD, NAS). Based on risk stratification, MCOs targeted care coordination and outreach to connect high risk women with behavioral and primary health care services.
- TennCare is working with the TDH to integrate CSMD data with TennCare data to better clinically engage TennCare members using opioids
- Focused provider education on appropriate prescribing habits and tapering of chronic opioid use

Tertiary Prevention


support active recovery for severe opioid dependence and addiction


Chronic Dependent and Addicted Users


- TennCare's MCOs significantly increasing resources and support for network of high-quality Medication Assisted Treatment (MAT) providers as part of TennCare directive to develoo broader OUD
- TennCare and MCOs Increasing outreach to highest risk chronic opioid use members to refer for treatment
- TennCare coordinating the lowering of TennCare-allowed maximum MED dosage for chronic opioid use with increased patient engagement

5

Wu, TennCare







MAT Provider Benefits

Benefits of Contracting as MAT Provider

Clinical and care coordination support from MCOs

Broadened TennCare MAT Pharmacy benefits Increased data on quality and health outcomes

Reimbursement from the MCOs for defined MAT services



Wu. TennCare

MAT Program Description: Overview

- The Buprenorphine MAT Program Description is the same for all three MCOs (BlueCare, Amerigroup and United Healthcare)
- The Program Description was developed based on national guidelines (i.e. ASAM,SAMHSA) and is in line with State of Tennessee OBOT guidelines
- This webinar will focus on buprenorphine
 - A separate program description exists for naltrexone

Buprenorphine Medication Assisted Treatment (MAT) Program Description Division of TennCare

Overview of the Opioid Use Disorder Medication Assisted Treatment Program

The Division of TennCare along with the contracted Managed Care Organizations (Amerigroup, BlueCare and United Healthcare) has determined the need for a comprehensive network of providers who offer specific treatment for members with opioid use disorder. These providers may be agencies or licensed independent practitioners, but all must attest to provide treatment as outlined in this program description to be included in this network.

Medication Assisted Treatment (MAT) for persons diagnosed with opioid-use disorder is the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach on the treatment of pulsations use disorders. Research shows that when treating substance-use disorders, a combination of medication and behavioral therapies is most constant. The uniform of treatment should be based on the need of the persons severed. The disorders while of the person of the product of the person of the use in treatment of coolid-use under which include the upernorphine consening products and nathrenore products.

Treatment with buprenorphine for opioid use disorders is considered an evidence-based best practice by the Substance Abuse and Meral Health Service Administration (SMRMS) Center and the American Society of Addiction Medicine (SAMI) for substance abuse treatment abuprenorphine MRT Program Description outlines treatment and clinical are restricted. expected of providers who prescribe buprenorphine products and professionals who provide respected of providers who prescribe buprenorphine products and professionals who provide expected of providers who prescribe huprenorphine products. For providers who prescribe naltreasene based products, refer to Mailtenanous ART Professional Services.

Treatment Elements

The required treatment elements for providers rendering Medication Assisted Treatment using buprenorphine are as follows:


 The preferred medication would be the buprenorphine/naloxone combination (as covered by the FennCare formularly for induction as well as stabilisation unless contraindicated (e.g. pregnancy) and then the buprenorphine monotherapy is recommended. The buprenorphine/naloxone combination serves to minimize diversion and intravenous abuse.


UHCCP MAT Program Description V1 4.17.18


10


TN

Vu. TennCare










Project ECHO®: Building Capacity in Primary Care

- Collaborative MCO initiative to establish holistic "best care" model for SUD treatment
- Model includes medication assisted treatment, behavioral health and peer supports
- Deploy Project ECHO training to MAT providers in TN
- Evaluate outcomes at system and practice team levels
- Expand the model and the training





15

WHAT QUESTIONS DO YOU HAVE?



THANK YOU

Nu. TennCar